D. Davidson

发表

Results of a phase Iii trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhoea

S. Chasan-Taber, E. Bouza, M. Dryden, 2008 .

Absorption of Colesevelam Hydrochloride in Healthy Volunteers

S. Burke, D. Davidson, Dennis Heller, 2002, The Annals of pharmacotherapy.

Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively.

D. Hunninghake, W. Insull, S. Burke, 2001, Atherosclerosis.

Distribution of Clostridium difficile strains from a North American, European and Australian trial of treatment for C. difficile infections: 2005-2007.

D. Gerding, S. Sambol, Stuart Johnson, 2009, Anaerobe.

Review article: tolevamer, a novel toxin‐binding polymer: overview of preclinical pharmacology and physicochemical properties

R. Barker, J. Marquis, D. Davidson, 2006, Alimentary pharmacology & therapeutics.

The emerging infectious challenge of clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences.

J Jaime Caro, J. Caro, J. O'brien, 2007, Infection control and hospital epidemiology.

Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.

T. Louie, D. Gerding, S. Chasan-Taber, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Results from Two Multinational, Randomized, Controlled Trials

T. Louie, D. Gerding, Stuart Johnson, 2014 .

O331 Metronidazole and vancomycin outcomes for Clostridium difficile -associated diarrhoea in a US hospital database

D. Davidson, B. Lahue, 2007 .

Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea.

T. Louie, S. Chasan-Taber, G. Garber, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The Emerging Infectious Challenge of Clostridium difficile-Associated Disease in Massachusetts Hospitals: Clinical and Economic Consequences

J. Caro, J. O'brien, D. Davidson, 2007, Infection Control & Hospital Epidemiology.

A new formulation of tolevamer, a novel nonantibiotic polymer, is safe and well-tolerated in healthy volunteers: a randomized phase I trial.

D. Davidson, J. Peppe, Andrew Porzio, 2008, British journal of clinical pharmacology.

A new formulation of tolevamer, a novel nonantibiotic polymer, is safe and well-tolerated in healthy volunteers: a randomized phase I trial.

D. Davidson, J. Peppe, Andrew Porzio, 2008, British journal of clinical pharmacology.